High dose chemotherapy and stem cell support in the treatment of germ cell cancer

Journal of Urology

Volumn 169, Issue 4, 2003, Pages 1229-1233

  Margolin, Kim ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Drug therapy; Germ cell and embryonal; Neoplasms; Stem cell transplantation

Indexed keywords

ALKYLATING AGENT; AMIFOSTINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; KERATINOCYTE GROWTH FACTOR; MESNA; OXAZAPHOSPHORINE DERIVATIVE; PACLITAXEL; THIOTEPA; THYMIDINE; VINBLASTINE;

ADVANCED CANCER; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLADDER DISEASE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; GERM CELL TUMOR; HEMORRHAGIC CYSTITIS; HUMAN; INTERMETHOD COMPARISON; LIVER TOXICITY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; STOMATITIS; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0037376295     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000055010.53977.e0     Document Type: Review

References (44)

1. Einhorn, L. H. and Donahue, J.: Cis-Diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med, 87: 293, 1977
2. Bosl, G. J., Yagoda, A., Golbey, R. B., Whitmore, W., Jr., Herr, H., Sogani, P. et al: Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors. Am J Med, 78: 423, 1985
3. Loehrer, P. J., Sr., Lauer, R., Roth, B. J., Williams, S. D., Kalasinski, L. A. and Einhorn, L. H.: Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med, 109: 540, 1988
4. Motzer, R. J., Cooper, K., Geller, N. L., Bajorin, D. F., Dmitrovsky, E., Herr, H. et al: The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer, 66: 2476, 1990
5. Motzer, R. J. and Bosl, G. J.: High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. J Natl Cancer Inst, 84: 1703, 1992
6. Shea, T. C., Flaherty, M., Elias, A., Eder, J. P., Antman, K., Begg, C. et al: A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol, 7: 651, 1989
7. Elias, A. D., Eder, J. P., Shea, T., Begg, C. B., Frei, E., 3rd and Antman, K. H.: High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol, 8: 170, 1990
8. Elias, A. D., Ayash, L. J., Eder, J. P., Wheeler, C., Drary, J., Weissman, L. et al: A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol, 9: 320, 1991
9. Wilson, W. H., Jain, V., Bryant, G., Cowan, K. H., Carter, C., Cottler-Fox, M. et al: Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol, 10: 1712, 1992
10. Elias, A. D., Ayash, L. J., Wheeler, C., Schwartz, G., Tepler, I., Gonin, R. et al: Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant, 15: 373, 1995
11. Fields, K. K., Elfenbein, G. J., Lazarus, H. M., Cooper, B. W., Perkins, J. B., Creger, R. J. et al: Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol, 13: 323, 1995
12. Broun, E. R., Nichols, C. R., Kneebone, P., Williams, S. D., Loehrer, P. J., Einhorn, L. H. et al: Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med, 117: 124, 1992
13. Nichols, C. R., Andersen, J., Lazarus, H. M., Fisher, H., Greer, J., Stadtmauer, E. A. et al: High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol, 10: 558, 1992
14. Barnett, M. J., Coppin, C. M., Murray, N., Nevill, T. J., Reece, D. E., Klingemann, H. G. et al: High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours. Br J Cancer, 68: 594, 1993
15. Rodenhuis, S., van der Wall, E., ten Bokkel Huinink, W. W., Schomagel, J. H., Richel, D. J. and Vlasveld, L. T.: Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer. Cancer Invest, 13: 355, 1995
16. Lampe, H., Dearnaley, D. P., Price, A., Mehta, J., Powles, R., Nicholls, J. et al: High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours. Eur J Cancer, 31A: 717, 1995
17. Motzer, R. J., Mazumdar, M., Bosl, G. J., Bajorin, D. F., Amsterdam, A. and Vlamis, V.: High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol, 14: 1098, 1996
18. Margolin, K., Doroshow, J. H., Ahn, C., Hamasaki, V., Leong, L., Morgan, R. et al: Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol, 14: 2631, 1996
19. Mandanas, R. A., Saez, R. A., Epstein, R. B., Confer, D. L. and Selby, G. B.: Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors. Bone Marrow Transplant, 21: 569, 1998
20. Bhatia, S., Abonour, R., Porcu, P., Seshadri, R., Nichols, C. R., Cornetta, K. et al: High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol, 18: 3346, 2000
21. Ayash, L. J., Clarke, M., Silver, S. M., Braun, T., Uberti, J., Ratanatharathorn, V. et al: Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review. Bone Marrow Transplant, 27: 939, 2001
22. Rick, O., Bokemeyer, C., Beyer, J., Hartmann, J. T., Schwella, N., Kingreen, D. et al: Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol, 19: 81, 2001
23. Bajorin, D. F., Sarosdy, M. F., Pfister, D. G., Mazumdar, M., Motzer, R. J., Scher, H. I. et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol, 11: 598, 1993
24. Horwich, A., Sleijfer, D., Fossa, S. B., Oliver, R. T., Cullen, M. H., Mead, G. M. et al: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/ European Organization for Research and Treatment of Cancer Trial. J Clin Oncol, 15: 1844, 1997
25. Blume, K. G., Forman, S. J., O'Donnell, M. R., Doroshow, J. H., Krance, R. A., Nademanee, A. P. et al: Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood, 69: 1015, 1987
26. Stemmer, S. M., Cagnoni, P. J., Shpall, E. J., Bearman, S. I., Matthes, S., Dufton, C. et al: High-dose paclitaxel, cyclophosphamide and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol, 14: 1463, 1996
27. Hensley, M. L., Schuchter, L. M., Lindley, C., Meropol, N. J., Cohen, G. I., Broder, G. et al: American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol, 17: 3333, 1999
28. Leong, L., Margolin, K., Doroshow, J. H., Longmate, J., Chow, W., Morgan, R. et al: Tandem cycles of taxol-based high-dose chemotherapy with stem cell rescue (HDCT) for poor-prognosis germ cell cancer (GCT) Proc Am Soc Clin Oncol, 18:, 346a, abstract 1332, 1999
29. Motzer, R. J., Mazumdar, M., Sheinfeld, J., Bajorin, D. F., Macapinlac, H. A., Bains, M. et al: Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol, 18: 1173, 2000
30. Beyer, J., Kramar, A., Mandanas, R., Linkesch, W., Greinix, A., Droz, J. P. et al: High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol, 14: 2638, 1996
31. McCaffrey, J. A., Mazumdar, M., Bajorin, D. F., Bosl, G. J., Vlamis, V. and Motzer, R. J.: Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol, 15-2559, 1997
32. Loehrer, P. J., Sr., Gonin, R., Nichols, C. R., Weathers, T. and Einhorn, L. H.: Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol, 16: 2500, 1998
33. Rosti, G., Pico, J. L., Wandt, V., Koza, V., Salvioni, R., Theodore, C. et al: High-dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors (GCT); first results of a prospective randomised trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94 study. Proc Amer Soc Clin Oncol, 34: 180a, abstract 716, 2002
34. Chou, T., Motzer, R. J., Tong, Y. and Bosl, G. J.: Computerized quantification of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst, 86: 1517, 1994
35. Motzer, R. J., Sheinfeld, J., Mazumdar, M., Bains, M., Mariani, T., Bacik, J. et al: Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol, 18: 2413, 2000
36. Norton, L. and Simon, R.: The Norton-Simon hypothesis revisited. Cancer Treat Rep, 70: 163, 1986
37. Motzer, R. J., Mazumdar, M., Sheinfeld, J., Bajorin, D. F., Macapinlac, H. A., Bains, M. et al: Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol, 18: 1173, 2000
38. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol, 15: 594, 1997
39. Bajorin, D. F. and Bosl, G. J.: The use of serum tumor markers in the prognosis and treatment of germ cell tumors. PPO Updates, 6: 1, 1992
40. Toner, G. C., Geller, N. L., Tan, C., Nisselbaum, J. and Bosl, G. J.: Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res, 50: 5904, 1990
41. Motzer, R. J., Mazumdar, M., Gulati, S. C., Bajorin, D. F., Lyn, P., Vlamis, V. et al: Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst, 85: 1828, 1993
42. Motzer, R. J., Mazumdar, M., Bajorin, D. F., Bosl, G. J., Lyn, P. and Vlamis, V.: High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol, 15: 2546, 1997
43. Mazumdar, M., Bajorin, D. F., Bacik, J., Higgins, G., Motzer, R. J. and Bosl, G. J.: Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol, 19: 2534, 2001
44. Bokemeyer, C., Gillis, A. J., Pompe, K., Mayer, F., Metzner, B., Schleucher, N. et al: Clinical impact of germ cell tumor cells in apheresis products of patients receiving high-dose chemotherapy. J Clin Oncol, 19: 3029, 2001